Zentalis Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Zentalis Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||
| current assets | ||||||||||||||||||||||
| cash and cash equivalents | 37,599,000 | 41,929,000 | 33,901,000 | 41,320,000 | 36,976,000 | 37,616,000 | 28,038,000 | 110,751,000 | 266,558,000 | 36,280,000 | 43,069,000 | 42,551,000 | 55,143,000 | 30,572,000 | 59,714,000 | 40,807,000 | 49,170,000 | 28,996,000 | 54,951,000 | 92,552,000 | 96,016,000 | 63,650,000 |
| marketable securities, available-for-sale | 249,041,000 | 278,373,000 | 349,932,000 | 389,409,000 | 451,368,000 | 405,886,000 | 286,428,000 | 356,239,000 | 379,175,000 | 400,078,000 | 258,797,000 | 325,984,000 | 201,730,000 | 274,884,000 | 137,175,000 | |||||||
| marketable equity securities | 16,791,000 | 12,151,000 | 19,174,000 | |||||||||||||||||||
| contracts receivable | 5,000,000 | |||||||||||||||||||||
| prepaid expenses and other current assets | 8,165,000 | 10,429,000 | 9,982,000 | 9,018,000 | 13,231,000 | 14,822,000 | 13,799,000 | 11,627,000 | 10,943,000 | 17,707,000 | 14,562,000 | 12,164,000 | 12,405,000 | 11,670,000 | 10,636,000 | 10,423,000 | 8,301,000 | 7,725,000 | 6,182,000 | 5,178,000 | 5,217,000 | 2,220,000 |
| total current assets | 311,596,000 | 342,882,000 | 386,066,000 | 400,270,000 | 439,616,000 | 503,806,000 | 496,718,000 | 528,264,000 | 563,929,000 | 410,226,000 | 451,933,000 | 433,890,000 | 467,626,000 | 301,282,000 | 350,770,000 | 377,565,000 | 259,449,000 | 306,354,000 | 345,104,000 | 372,736,000 | 238,481,000 | 66,009,000 |
| property and equipment | 3,087,000 | 3,247,000 | 4,699,000 | 5,016,000 | 5,337,000 | 5,679,000 | 5,819,000 | 6,393,000 | 6,650,000 | 6,880,000 | 7,705,000 | 8,027,000 | 8,218,000 | 8,480,000 | 8,148,000 | 4,698,000 | 2,251,000 | 1,508,000 | 1,099,000 | 471,000 | 481,000 | 519,000 |
| operating lease right-of-use assets | 31,175,000 | 31,925,000 | 32,528,000 | 33,403,000 | 33,474,000 | 34,726,000 | 35,916,000 | 36,184,000 | 36,584,000 | 37,475,000 | 42,373,000 | 42,646,000 | 43,305,000 | 43,644,000 | 44,691,000 | 693,000 | 1,195,000 | 1,901,000 | 2,520,000 | 1,925,000 | 2,090,000 | 2,276,000 |
| prepaid expenses and other assets | 3,222,000 | 3,340,000 | 4,417,000 | 5,609,000 | 6,836,000 | 6,851,000 | 6,818,000 | 8,511,000 | 7,918,000 | 9,495,000 | 9,723,000 | 10,232,000 | 11,938,000 | 10,164,000 | 7,040,000 | 6,042,000 | 4,794,000 | 2,790,000 | 2,976,000 | 4,245,000 | 3,218,000 | 2,353,000 |
| restricted cash | 2,627,000 | 2,627,000 | 2,627,000 | 2,627,000 | 2,681,000 | 2,681,000 | 2,681,000 | 2,627,000 | 2,627,000 | 2,627,000 | 243,000 | 243,000 | 243,000 | 243,000 | 3,264,000 | 1,320,000 | 1,320,000 | 411,000 | 411,000 | |||
| total assets | 351,707,000 | 384,021,000 | 430,337,000 | 450,661,000 | 491,680,000 | 557,479,000 | 551,688,000 | 585,715,000 | 621,444,000 | 489,342,000 | 539,310,000 | 529,193,000 | 567,856,000 | 405,677,000 | 454,507,000 | 435,081,000 | 283,962,000 | 328,353,000 | 365,555,000 | 393,233,000 | 257,217,000 | 87,629,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||
| current liabilities | ||||||||||||||||||||||
| accounts payable | 3,719,000 | 7,769,000 | 7,438,000 | 8,202,000 | 20,440,000 | 10,502,000 | 14,926,000 | 14,264,000 | 12,305,000 | 12,818,000 | 11,247,000 | 9,820,000 | 12,041,000 | 13,163,000 | 11,590,000 | 8,046,000 | 8,273,000 | 8,337,000 | 8,661,000 | 5,437,000 | 4,217,000 | 7,019,000 |
| accrued expenses | 35,303,000 | 41,661,000 | 45,287,000 | 46,675,000 | 46,252,000 | 44,296,000 | 54,441,000 | 44,654,000 | 39,454,000 | 43,540,000 | 45,400,000 | 44,241,000 | 36,595,000 | 30,322,000 | 32,354,000 | 31,369,000 | 25,304,000 | 24,460,000 | 19,940,000 | 18,469,000 | 11,350,000 | 9,920,000 |
| total current liabilities | 39,022,000 | 49,430,000 | 52,725,000 | 54,877,000 | 66,692,000 | 54,798,000 | 69,367,000 | 58,918,000 | 51,759,000 | 56,358,000 | 56,647,000 | 54,061,000 | 48,636,000 | 43,485,000 | 43,944,000 | 39,415,000 | 33,577,000 | 32,797,000 | 28,601,000 | 23,906,000 | 15,567,000 | 16,939,000 |
| long-term lease liability | 37,690,000 | 38,651,000 | 39,577,000 | 40,457,000 | 41,318,000 | 42,616,000 | 43,150,000 | 43,266,000 | 44,027,000 | 44,771,000 | 45,166,000 | 44,459,000 | ||||||||||
| other long-term liabilities | 500,000 | 558,000 | 849,000 | 996,000 | 1,089,000 | 1,294,000 | 1,780,000 | 1,634,000 | 2,376,000 | 1,792,000 | 2,620,000 | 45,169,000 | 45,072,000 | 44,978,000 | 296,000 | 438,000 | 1,097,000 | 1,031,000 | 1,262,000 | 1,484,000 | ||
| total liabilities | 77,212,000 | 88,639,000 | 93,151,000 | 96,330,000 | 109,099,000 | 98,708,000 | 114,297,000 | 103,818,000 | 98,162,000 | 103,677,000 | 105,286,000 | 100,455,000 | 95,033,000 | 90,011,000 | 90,025,000 | 41,085,000 | 36,353,000 | 35,715,000 | 32,178,000 | 27,400,000 | 19,292,000 | 20,886,000 |
| commitments and contingencies | ||||||||||||||||||||||
| equity | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||
| common stock | 72,000 | 72,000 | 71,000 | 71,000 | 71,000 | 70,000 | 70,000 | 70,000 | 70,000 | 59,000 | 59,000 | 57,000 | 57,000 | 46,000 | 45,000 | 45,000 | 41,000 | 41,000 | 41,000 | 41,000 | 36,000 | |
| additional paid-in capital | 1,403,912,000 | 1,397,626,000 | 1,390,952,000 | 1,359,589,000 | 1,349,135,000 | 1,336,416,000 | 1,323,576,000 | 1,309,696,000 | 1,295,520,000 | 1,045,568,000 | 1,031,462,000 | 972,111,000 | 961,205,000 | 734,997,000 | 723,593,000 | 702,855,000 | 529,019,000 | 519,030,000 | 509,339,000 | 501,522,000 | 339,160,000 | |
| accumulated other comprehensive income | 59,000 | 358,000 | 1,594,000 | 140,000 | 773,000 | -125,000 | 32,000 | 94,000 | 50,000 | 36,000 | 23,000 | 4,000 | ||||||||||
| accumulated deficit | -1,129,548,000 | -1,102,674,000 | -1,054,395,000 | -1,006,923,000 | -966,765,000 | -878,488,000 | -888,556,000 | -827,639,000 | -772,111,000 | -659,584,000 | -596,365,000 | -541,394,000 | -486,993,000 | -418,636,000 | -359,559,000 | -309,500,000 | -305,309,000 | -250,735,000 | -200,834,000 | -160,531,000 | -125,976,000 | -99,119,000 |
| total stockholders’ equity | 274,495,000 | 295,382,000 | 354,331,000 | 382,581,000 | 458,771,000 | 481,768,000 | 523,141,000 | 385,487,000 | 428,504,000 | 472,490,000 | 315,298,000 | 393,432,000 | 223,845,000 | |||||||||
| total liabilities and stockholders’ equity | 351,707,000 | 384,021,000 | 450,661,000 | 491,680,000 | 557,479,000 | 585,715,000 | 621,444,000 | 489,342,000 | 529,193,000 | 567,856,000 | 405,677,000 | 435,081,000 | 283,962,000 | |||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||
| marketable debt securities, available for sale | 318,009,000 | |||||||||||||||||||||
| goodwill | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | 3,736,000 | |||
| liabilities and stockholders' equity | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2024 and 2023 | ||||||||||||||||||||||
| accumulated other comprehensive income/ | 558,000 | 2,194,000 | ||||||||||||||||||||
| total stockholders' equity | 337,186,000 | 437,284,000 | 433,803,000 | 363,954,000 | 268,386,000 | |||||||||||||||||
| noncontrolling interests | 107,000 | 129,000 | 141,000 | 178,000 | 221,000 | 234,000 | 333,000 | 368,000 | 528,000 | 564,000 | 23,764,000 | 24,252,000 | 24,795,000 | 24,778,000 | 24,701,000 | 6,712,000 | ||||||
| total equity | 337,186,000 | 354,331,000 | 382,581,000 | 458,771,000 | 437,391,000 | 481,897,000 | 523,282,000 | 385,665,000 | 434,024,000 | 428,738,000 | 472,823,000 | 315,666,000 | 364,482,000 | 393,996,000 | 247,609,000 | 292,638,000 | 333,377,000 | 365,833,000 | 237,925,000 | |||
| total liabilities and stockholders' equity | 430,337,000 | 551,688,000 | 539,310,000 | 454,507,000 | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||
| marketable securities, available for sale | 454,881,000 | 394,302,000 | 280,173,000 | 269,385,000 | 283,554,000 | |||||||||||||||||
| investment in zentera therapeutics | 18,903,000 | 21,213,000 | 28,035,000 | 30,406,000 | 35,744,000 | 37,495,000 | 39,326,000 | |||||||||||||||
| deferred tax liability | 756,000 | 853,000 | 1,225,000 | 1,325,000 | 1,548,000 | 1,622,000 | 1,670,000 | 2,480,000 | 2,480,000 | 2,480,000 | 2,463,000 | 2,463,000 | 2,463,000 | |||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2023 and 2022 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||
| accumulated other comprehensive loss | -359,000 | -338,000 | -556,000 | -1,353,000 | -2,270,000 | -1,779,000 | -1,109,000 | |||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2022 and 2021 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||
| accounts receivable from government grants | 4,000 | 108,000 | 5,000 | 248,000 | 417,000 | 122,000 | 73,000 | 139,000 | ||||||||||||||
| in-process research and development | 8,800,000 | 8,800,000 | 8,800,000 | 8,800,000 | 8,800,000 | 8,800,000 | ||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2021 and 2020 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||
| deferred financing costs | 716,000 | 3,525,000 | ||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||
| liabilities, convertible preferred units and equity | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||
| total liabilities and equity | 328,353,000 | |||||||||||||||||||||
| convertible preferred units; redemption value of 146,944 at december 31, 2019 | ||||||||||||||||||||||
| class a common units; 20,000,000 units authorized at december 31, 2019; 5,601,478 units issued and outstanding at december 31, 2019 | ||||||||||||||||||||||
| class b common units 3,458,522 units authorized at december 31, 2019; 2,670,668 units issued and outstanding at december 31, 2019 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2020 | ||||||||||||||||||||||
| total stockholders' equity/members' | 308,582,000 | |||||||||||||||||||||
| total liabilities, convertible preferred units and equity | 365,555,000 | 393,233,000 | 257,217,000 | |||||||||||||||||||
| liabilities, convertible preferred units and equity/ | ||||||||||||||||||||||
| convertible preferred units; redemption value of 146,944,000 at december 31, 2019 | ||||||||||||||||||||||
| class a common units; 20,000,000 units authorized; 5,601,478 units issued and outstanding at december 31, 2019 | ||||||||||||||||||||||
| class b common units, 3,458,522 units authorized; 2,670,668 units issued and outstanding at december 31, 2019 | ||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2020 | ||||||||||||||||||||||
| total stockholders’ equity/members’ | 341,055,000 | 213,224,000 | ||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2020 | ||||||||||||||||||||||
| liabilities, convertible preferred units and deficit | ||||||||||||||||||||||
| convertible preferred units; redemption value of 162,120,000 and 146,944,000 at march 31, 2020 and december 31, 2019, respectively | 155,934,000 | |||||||||||||||||||||
| class a common units; 20,000,000 units authorized at march 31, 2020 and december 31, 2019; 5,601,478 units issued and outstanding at march 31, 2020 and december 31, 2019 | 709,000 | |||||||||||||||||||||
| class b common units, 3,458,522 units authorized at march 31, 2020 and december 31, 2019; 2,607,309 and 2,670,668 units issued and outstanding at march 31, 2020 and december 31, 2019, respectively | 2,507,000 | |||||||||||||||||||||
| total zentalis pharmaceuticals, llc members’ deficit | -95,903,000 | |||||||||||||||||||||
| total deficit | -89,191,000 | |||||||||||||||||||||
| total liabilities, convertible preferred units and deficit | 87,629,000 |
We provide you with 20 years of balance sheets for Zentalis Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Zentalis Pharmaceuticals. Explore the full financial landscape of Zentalis Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Zentalis Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.